SI-BONE SIBN 深 滬
等待開盤 04-03 09:30:00 美东时间
13.02
+0.010
+0.08%
華盛通- 最 高13.17
- 今 開12.73
- 成交量 36.57万股
- 最 低 12.37
- 昨 收 13.01
- 總市值 5.75亿
- 52周最高 21.89
- 市盈率 靜 --
- 換手率 0.83%
- 52周最低 12.15
- 委 比 -91.56%
- 總股本 4416.53万
- 歷史最高 37.21
- 量 比 0.76
- 振 幅 6.15%
- 歷史最低 7.20
- 每 手 1
- 風險率 2.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多施乐辉手持骨科机器人，亮相盛会
全球骨科巨头Smith&Nephew（施乐辉）宣布，将在即将举行的美国骨科医师学会年会（AAOS2026）上，重点展示手持外科机器人。 在直觉外科（达...
03-05 17:30
Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026
Smith+Nephew will showcase its advanced robotics and digital solutions for hip, knee, and shoulder procedures, along with innovative trauma and extremities products, at the AAOS Annual Meeting. Highlights include the CORI Surgical System, CORI SHOULDER Platform for robotic shoulder arthroplasty, and new implant options. The company also announced partnerships to expand its ASC enterprise offering, offering end-to-end solutions for ASC development...
03-03 18:00
美股大行评级 | 潜在涨幅243.25%！泰利克斯制药获花旗升目标价至22.5美元，维持"买入"评级
今日重点评级关注：花旗：维持Telix Pharmaceuticals"买入"评级，目标价从22美元升至22.5美元；摩根士丹利：维持Vir Biotechnology"超配"评级，目标价从20美元升至24美元
02-25 11:03
TD Cowen Maintains Buy on SI-BONE, Raises Price Target to $22
TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $21 to $22.
02-25 01:08
电话会总结 ｜ SI-BONE(SIBN)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据SI-BONE业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 第四季度全球营收5,630万美元，同比增长15% - 美国营收5,350万美元，同比增长13.9% - 国际营收290万美元，同比增长38.8% - 全年营收2.009亿美元，同比增长20.2% - 美国全年营收1.911亿美元，同比增长20.6% **盈利能力：** - 第四季度毛利润4,450万美元，同比增长14.8% - 全年毛利润1.599亿美元，同比增长21% - 第四季度毛利率79%，全年毛利率79.6% - 第四季度净亏损160万美元（
02-24 12:29
SI-BONE forecasts 2026 worldwide revenue of $228.5 million to $232.5 million
SI-BONE forecasts 2026 worldwide revenue of $228.5 million to $232.5 million SI-BONE issued 2026 worldwide revenue guidance of $228.5 million to $232.5 million, implying about 14% to 16% year-over-year growth, and guided to gross margin of about 78% with operating expenses up roughly 12.5% at the mi
02-24 05:39
SI-BONE Q4 revenue rises
SI-BONE Q4 revenue rises Overview Bone solutions firm's Q4 revenue grew 15%, slightly beating analyst expectations Company achieved positive adjusted EBITDA of $5.1 mln, improving by 176.2% Outlook SI-BONE expects 2026 revenue between $228.5 mln and $232.5 mln, ~14% to ~16% growth Company estimates
02-24 05:17
SI-BONE Q4 Earnings Assessment
SI-BONE (NASDAQ:SIBN) reported its Q4 earnings results on Monday, February 23, ...
02-24 05:12
SI-BONE Sees FY2026 Sales $228.500M-$232.500M vs $229.904M Est
SI-BONE (NASDAQ:SIBN) sees FY2026 sales of $228.500 million-$232.500 million vs $229.904 million analyst estimate.
02-24 05:11
SI-BONE Q4 EPS $(0.04) Beats $(0.12) Estimate, Sales $56.350M Beat $55.397M Estimate
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.12) by 67.48 percent. This is a 63.64 percent increase over losses of $(0.11) per share from the same
02-24 05:10
